Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.77

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have earned an average rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $5.77.

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC boosted its holdings in shares of CytomX Therapeutics by 1.4% in the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock worth $3,324,000 after acquiring an additional 37,739 shares during the period. Assenagon Asset Management S.A. lifted its holdings in CytomX Therapeutics by 32.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock worth $1,940,000 after purchasing an additional 405,669 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in CytomX Therapeutics by 1.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 16,359 shares during the period. Congress Park Capital LLC grew its holdings in CytomX Therapeutics by 5.4% during the 3rd quarter. Congress Park Capital LLC now owns 1,216,008 shares of the biotechnology company’s stock valued at $1,435,000 after buying an additional 62,788 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in CytomX Therapeutics by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after buying an additional 34,032 shares in the last quarter. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

CytomX Therapeutics Stock Performance

Shares of CTMX stock opened at $1.02 on Monday. The firm has a market cap of $79.83 million, a price-to-earnings ratio of 6.00 and a beta of 1.06. CytomX Therapeutics has a 52 week low of $0.83 and a 52 week high of $5.85. The firm’s 50-day simple moving average is $1.07 and its two-hundred day simple moving average is $1.29.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The company had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $18.92 million. During the same quarter in the previous year, the firm posted $0.04 EPS. Analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.